Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-07-02

Clinical Trial Update: A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial to evaluate safety and efficacy of baricitinib in participants with diabetic kidney disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-07-02